Mr. Sharma joined Genesys Capital in 2020 as an Associate, focusing on exploring cutting edge life sciences technologies and supporting current portfolio companies. He currently serves as a Board Observer at Veralox Therapeutics, Inc, Feldan Therapeutics, and CryoStasis.

Before Genesys, Mr. Sharma worked at adMare Bioinnovations, where he was responsible for proactive identification of new opportunities, deal sourcing and financial valuations. Prior to his time at adMare, he served as a Management Consultant providing primary strategic insights to big pharma.

He has also held various scientific roles in an early drug discovery group at Eisai Inc. and in a clinical biomarker group at Alexion Pharma. He spent his early career in academic research at Abramson Cancer Center at University of Pennsylvania.

Mr. Sharma holds a Bachelor of Technology from Amity University Gurgaon, a Master of Biotechnology from the University of Pennsylvania, and an MBA from the UBC Sauder School of Business at University of British Columbia.

• 

  Senior Associate in Genesys Capital

  We invest in early stage life science companies that are poised to change lives for the bette